Management of Recurrent HCC After Liver Transplantation

Basit Öğe Kaydı
dc.authoridIsik, Burak/0000-0002-2395-3985
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridSARICI, KEMAL BARIŞ/0000-0001-9595-1906
dc.authorwosidIsik, Burak/A-6657-2018
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidSARICI, KEMAL BARIŞ/ABI-4356-2020
dc.contributor.authorSarici, Baris
dc.contributor.authorIsik, Burak
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:48:48Z
dc.date.available2024-08-04T20:48:48Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground Liver transplantation is the best treatment option for hepatocellular carcinoma (HCC). Although centers use strict selection criteria, there is a risk of recurrence, reaching up to 20% which are mostly observed within two years following the procedure. The survival after the recurrence is poor and it has been reported to be between 7-16 months. This poor prognosis is due to the systemic course of the recurrence even its presentation is local initially. Results The clinical management and treatment algorithm of recurrence is challenging and there is no guideline regarding the situation. Staging of the disease and multi-disciplinary approach are important. The decision for choice of treatment is given depending on the localization and spread of the recurrence. Adjusting and switching the immunosuppressive therapy should be the first attempt. When the recurrence is limited or confined to resectable regions, surgery should be the choice of treatment. Multiple recurrence sites such as adrenal glands, lung, lymph nodes are not contraindication for curative surgery. Resection of the graft for intrahepatic recurrence is the most beneficial procedure for survival. If resection is not possible due to advanced hepatic disease, loco-regional therapies such as TACE, RF, microwave ablation should be considered. SBRT may be an alternative both for hepatic and extra-hepatic recurrence. In case of systemic disease, sorafenib should be the drug choice.en_US
dc.identifier.doi10.1007/s12029-020-00498-6
dc.identifier.endpage1199en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid32839944en_US
dc.identifier.scopus2-s2.0-85089729906en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1197en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00498-6
dc.identifier.urihttps://hdl.handle.net/11616/99473
dc.identifier.volume51en_US
dc.identifier.wosWOS:000562326000003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectLiver transplantationen_US
dc.subjectLocoregional therapiesen_US
dc.subjectRecurrenceen_US
dc.titleManagement of Recurrent HCC After Liver Transplantationen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu